Granular Cell Tumor of the Breast: A Case Report and a Brief Review of the Literature

Read full text
Authors: Jennifer Paz, Anthony Shams, Nathaniel Ball, Sierra Wolfe, Oscar Ramos, Jessica Jahoda, Mohamed Aziz
Cited by: 0

Abstract

Granular cell tumor (GCT) of the breast is a rare, typically benign neoplasm of Schwann cell origin, which frequently presents a significant diagnostic challenge due to its ability to clinically and radiologically mimic invasive breast carcinoma. We present the case of a 45-year-old female who presented with a palpable, firm, non-mobile mass in the right upper inner quadrant of her breast. Diagnostic imaging was highly suspicious for malignancy, with mammography revealing a high-density, spiculated, irregular mass with architectural distortion (BI-RADS 5), and ultrasound demonstrating an irregular, hypoechoic mass with severe posterior acoustic shadowing and a "taller-than-wide" orientation. Core needle biopsy was performed due to the high suspicion of malignancy. Histopathological examination revealed nests and sheets of large, polygonal cells with abundant granular, eosinophilic cytoplasm. Immunohistochemistry (IHC) studies were critical for definitive diagnosis, showing strong positivity for S100 protein and SOX10, and granular positivity for CD68, while being negative for cytokeratin markers (AE1/AE3, CAM 5.2). This immunoprofiling confirmed the diagnosis of benign GCT. The patient was successfully treated with complete surgical excision (R0 resection) and has remained free of local recurrence at three years of follow-up. This case underscores the critical role of tissue diagnosis and characteristic IHC in differentiating this rare benign entity from malignant breast lesions, thereby preventing unnecessary aggressive treatment.

Fields of Study & Subjects

Tumors and Oncological Cases Breast Lesions and Carcinomas Neurofibromatosis and Schwannoma Cases

Publication details

Journal / source
World Journal of Biology Pharmacy and Health Sciences
Volume
25
Issue
2
Pages
051–073
Publication date
8 February 2026